Catherine Manya Rohloff

This inventor holds 25 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Intarcia Therapeutics, Inc., Durect Corporation. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Manya Rohloff. Retrieved from https://idiyas.com/inventor/catherine-manya-rohloff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 13)

% Patents Active = 64.0

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.4

ph-index = 20

Forward Citations = 610(Granted Patents)

Location History:

Cupertino, CA (US) (2011 - 2012)
Los Altos, CA (US) (2010 - 2022)

Company Filing History:

24 out of 68

Intarcia Therapeutics, Inc.

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

Insulinotropic Peptide

Osmotic Delivery Device

Pharmaceutical Formulations

Suspension Vehicle

Particle Formulation

Continuous Delivery

Non-Aqueous Vehicles

Polyoxaester

Implantable Delivery Systems

Beneficial Agents

Viscous Liquid

Composition and Dosage Form

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11246913 - Suspension formulation comprising an insulinotropic peptide (2022-02-15),

2. 10441528 - Devices, formulations, and methods for delivery of multiple beneficial agents (2019-10-15),

3. 10363287 - Method of manufacturing an osmotic delivery device (2019-07-30),

4. 9724293 - Methods of manufacturing viscous liquid pharmaceutical formulations (2017-08-08),

5. 9682127 - Osmotic delivery device comprising an insulinotropic peptide and uses thereof (2017-06-20),

6. 9572889 - Devices, formulations, and methods for delivery of multiple beneficial agents (2017-02-21),

7. 9526763 - Solvent/polymer solutions as suspension vehicles (2016-12-27),

8. 9095553 - Solvent/polymer solutions as suspension vehicles (2015-08-04),

9. 8940316 - Osmotic delivery comprising an insulinotropic peptide and uses thereof (2015-01-27),

10. 8926595 - Devices, formulations, and methods for delivery of multiple beneficial agents (2015-01-06),

11. 8496943 - Non-aqueous single phase vehicles and formulations utilizing such vehicles (2013-07-30),

12. 8460694 - Solvent/polymer solutions as suspension vehicles (2013-06-11),

13. 8440226 - Solvent/polymer solutions as suspension vehicles (2013-05-14),

14. 8398967 - Particle formulations for use in pharmaceutical compositions (2013-03-19),

15. 8343140 - Devices, formulations, and methods for delivery of multiple beneficial agents (2013-01-01),

Title: The Innovative Contributions of Catherine Manya Rohloff

Introduction: Catherine Manya Rohloff, based in Los Altos, California, is a prolific inventor with an impressive portfolio of 25 patents. Her work primarily focuses on the development of innovative formulations and delivery systems for beneficial agents, particularly in the field of biomedical technology.

Latest Patents: Rohloff's latest patents reflect her commitment to advancing medical science. One notable invention is a suspension formulation comprising an insulinotropic peptide, which includes glucagon-like peptide-1 (GLP-1) or exenatide. This formulation employs a non-aqueous, single-phase vehicle that showcases viscous fluid characteristics, combined with a stabilizing component to ensure the efficacy of the insulinotropic peptide. Additionally, she has developed devices for delivering these formulations. Another significant patent relates to osmotic delivery devices that facilitate the concurrent administration of two or more beneficial agents. This invention not only improves drug delivery methods but also enhances the treatment of various diseases by utilizing innovative formulations.

Career Highlights: Throughout her career, Catherine has contributed her expertise to multiple organizations, including Intarcia Therapeutics, Inc. and Durect Corporation. Her roles at these companies have significantly influenced advancements in drug delivery systems and therapeutic formulations.

Collaborations: Rohloff has collaborated with notable individuals in her field, including Thomas R. Alessi and Ryan D. Mercer. These partnerships have fostered innovative approaches in her work, leading to successful patent applications and ultimately improving healthcare outcomes.

Conclusion: Catherine Manya Rohloff's contributions to the field of biomedical technology through her innovative patents and collaborations highlight her role as a leader in the industry. Her work stands as a testament to the importance of innovation and research in developing effective solutions for healthcare challenges.

Profile summary based on public USPTO records.